Tag: Tysabri
Enhanced Atypical Lymphocytes in Natalizumab-Treated MS
Enhanced fraction of atypical lymphocytes, especially binucleated and plasmacytoid lymphocytes
Tysabri Impacts Seroconversion in John Cunningham Virus
Over 14.8 months, natalizumab treatment linked to 15.9 percent increase of value in JCV+ patients
